Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
September 7, 2021
Assignees:
Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
Abstract: Provided are methods for disrupting biofilms and/or preventing the formation of biofilms. Further provided are random-sequence peptide mixtures for use in disrupting bacterial biofilms. The random-sequence peptides include hydrophobic and/or cationic amino acids, and the ratio of the total hydrophobic and cationic amino acids in the mixture is predefined.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
August 31, 2021
Assignee:
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents.
Type:
Grant
Filed:
November 4, 2015
Date of Patent:
August 10, 2021
Assignee:
LYTIX BIOPHARMA AS
Inventors:
Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Laurence Zitvogel, Takahiro Yamazaki, Oystein Rekdal, John Sigurd Mjoen Svendsen
Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
Abstract: Provided is a highly sensitive and less expensive lectin-immobilized base material (for example, a lectin plate), such as lectin-immobilized base material having stable qualities and being able to be sufficiently washed after a target sugar chain-containing antigen binds thereto. Further provided is a method for immobilizing lectin to a base material therefor. Particularly provided are: a method whereby a lectin-peptide fusion, in which a peptide capable of adsorbing to a base material surface such as a polystyrene (PS) tag is fused with the N-terminal side or C-terminal side of lectin capable of recognizing a target sugar chain, is immobilized on the peptide side to a base material; and a lectin-immobilized base material produced by this method. By using the lectin-immobilized base material, a target sugar chain-containing antigen can be highly sensitively and evenly measured and, moreover, target sugar chain-containing cells, etc. can be separated (concentrated and harvested).
Type:
Grant
Filed:
April 11, 2018
Date of Patent:
August 3, 2021
Assignees:
National Institute of Advanced Industrial Science and Technology, Nissan Chemical Corporation, National University Corporation Kyoto Institute of Technology
Abstract: The present disclosure relates to methods of preparing and crystallizing ?-turn cyclic peptidomimetic salts of formula I: where R1, R2, R3, R4, R5, R6, R7, R8, R10, X, Y and n are as defined in the specification. The present disclosure provides a more efficient route for preparing a crystalline form of ?-turn cyclic peptidomimetic compounds and salts thereof.
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
August 3, 2021
Assignee:
MIMETOGEN PHARMACEUTICALS, INC
Inventors:
Sébastien Rocchi, Chantal Devin, Wei Tian, Martin Bohlin
Abstract: In various embodiments constructs are provided for the delivery of an effector molecule into a cell. In certain embodiments the construct comprises a cell penetrating peptide (CPP) attached to an effector that is to be delivered into a cell, where the cell penetrating peptide comprises a Zika cell penetrating peptide (Zika CPP), and the effector is selected from the group consisting of a protein, a nucleic acid, an organic compound, a nanoparticle, a viral particle, and the like.
Abstract: Provided are polypeptides and compositions comprising novel HSP-binding peptides. Such polypeptides and compositions are particularly useful as immunotherapeutics (e.g., cancer vaccines). Also provided are methods of inducing a cellular immune response using such polypeptides and compositions, methods of treating a disease using such polypeptides and compositions, kits comprising such polypeptides and compositions, and methods of making such compositions.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
July 20, 2021
Assignee:
AGENUS INC.
Inventors:
Mark Arthur Findeis, Benjamin Maxime Morin, Bishnu Joshi
Abstract: A composition in the form of an injectable aqueous solution, with pH from 3.5 to 4.4, including at least human insulin A21G and at least one glucagon suppressor with prandial action. In an embodiment, the glucagon suppressor with prandial action is selected from an amylin analog or an amylin receptor agonist or a GLP-1 analog or a GLP-1 receptor agonist (GLP-1 RA). In an embodiment, the glucagon suppressor with prandial action is an amylin analog or an amylin receptor agonist. In an embodiment, the glucagon suppressor peptide with prandial action is pramlintide. Also, a method for obtaining human insulin A21G, includes at least one step of reacting human insulin A21G, B31R, B32R (insulin glargine) with rat carboxypeptidase B at an insulin/carboxypeptidase ratio from 500 to 2000, at a pH from 7.5 to 8.5 and a temperature from 20 to 30° C. for 10 to 20 hours.
Abstract: This disclosure comprises devices and methods for determining the identity of individual protein molecules in a complex mixture by unfolding the protein into a polypeptide, tagging selected residues on the polypeptide with selected oligonucleotide sequence tags that recognize selected residues on said polypeptide, and then detecting the oligonucleotide sequence tags.
Abstract: Processes for preparing compounds of Formula (1) and Formula (2) are described, wherein X, Y, Z, R1-R7, L and n are defined herein. Intermediates useful in the preparation of the compounds of Formula (1) and Formula (2) are also described.
Type:
Grant
Filed:
February 4, 2020
Date of Patent:
July 6, 2021
Assignee:
ONKURE, INC.
Inventors:
Anthony D. Piscopio, Xiaoyong Fu, Feng Shi, Huayan Liu, Zhifeng Li
Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
Type:
Grant
Filed:
August 18, 2020
Date of Patent:
July 6, 2021
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li
Abstract: A two-layer gradient coating article is provided that is operable to cause selective adhesion and directional migration of endothelial cells. The first layer includes cell-resisting polymers that repels cells, the second layer includes one layer of peptides that has affinity to and binds specifically to endothelial cells. Furthermore, the peptides are distributed in a gradient, in which attached ECs migrate towards the direction of increased concentration, thus enriching the ECs to a desired locus. The combination of a cell-repelling layer and a graded affinity peptide produces a unique result of selective adhesion, directional migration, thus local enrichment of endothelial cells. A method for using such gradient coating article and its potential use in treating cardiovascular diseases are also provided. The invention provides an inexpensive, stable and effective means for attracting ECs to desirable locations.
Abstract: The present disclosure is concerned with dipeptide analogs that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, methods for immunotherapy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
June 29, 2021
Assignees:
Southern Research Institute, UAB Research Foundation
Inventors:
Mark J. Suto, Vandana Gupta, Bini Mathew, Joanne Murphy-Ullrich
Abstract: The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated. For example, a T cell may be recombinantly modified for use in adoptive immunotherapy.
Abstract: The present disclosure relates to compounds useful in the treatment, imaging, and/or diagnosis of Epstein-Barr virus (EBV)-positive cells, such as cancer.
Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3?). These molecules compete with CD3? for binding to a CD3? binding domain. e.g. a CD3? binding domain of an antibody, and are capable of detecting antibodies against CD3?. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3? antibody purification and the detection of anti-CD3? antibodies in biological samples.
Type:
Grant
Filed:
July 14, 2015
Date of Patent:
June 29, 2021
Assignees:
BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, JPT Peptide Technologies GmbH
Inventors:
Ugur Sahin, Laura Marie Kring, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt, Ulf Reimer, Karsten Schnatbaum
Abstract: Antimicrobial molecules, their synthesis and use as antimicrobial treatments are described. The antimicrobial compounds are teixobactin analogues. Methods of synthesizing antimicrobial teixobactin analogues are also provided. Antibiotic therapeutics comprising antimicrobial teixobactin analogues are provided, along with methods of and formulations for treating microbial infections using such antimicrobial teixobactin analogues. Prodrugs formed using esterified forms of antimicrobial teixobactin analogues may also be provided.
Type:
Grant
Filed:
April 17, 2017
Date of Patent:
June 29, 2021
Assignee:
The Regents of the University of California